bioMérieux S.A. (BIM) Is Yet to See Trading Action on Mar 14

March 14, 2018 - By Migdalia James

Shares of bioMérieux S.A. (EPA:BIM) closed at 66.3 yesterday. bioMérieux S.A. currently has a total float of 118.34 million shares and on average sees 122,762 shares exchange hands each day. The stock now has a 52-week low of 48.3 and high of 79.8.

CAC 40: Reflecting Europe’s Corporate Strength

Europe is not just all about good education systems, next-generation innovations, and beautiful tourist destinations. The region is also about a compelling economy that has already been through the worst yet continues to remain resilient. It economy helps companies like bioMérieux S.A. to survive at the market.

One of the main reasons behind its success is its competitive and growing equity market. The corporate sector is any economy’s hope, which is why Europe highly values good corporate governance. This is basically what lures investors in the European equity market. It also lures them to the companies like bioMérieux S.A., with potential and good liquidity.

What Makes Europe’s Economy a Success

Euronext is the leading stock exchange in Europe. It is situated in five different cities— Amsterdam, Brussels, Lisbon, London, and Paris, each of which have different indices. The leading indices include AEX, AMX, AScX, BEL 20, CAC 40, Euronext 100, Next 150, PSI 20, among others.

France’s Euronext Paris, formerly known as Paris Bourse is the leading stock exchange. The top 40 stocks listed on it are weighed on the CAC 40. The companies are monitored based on market capitalization using a base value of 1,000.

It is important not only to become one of CAC parts, like bioMérieux S.A. but to stay there. The components of the CAC 40 are reviewed by the Index Steering Committee quarterly, particularly every third Friday of each month of March, June, September, and December. If necessary, they are capped at 15% every review. Any changes made reflect not earlier than two weeks after the particular review date that they had been decided upon.

The movement of the CAC 40 is in increments of 0.50. The main currency on the CAC 40 is euro. To trade, a typical margin of 2% and a minimum trade size of one index are required. Regular session begins and ends at 6:01 a.m. and 7:59 p.m., respectively.

CAC 40 History

The name of CAC 40 was derived from the former automation system of Euronext Paris, CotationAssistéeenContinu.

The base value of 1,000 was set on December 31, 1987. Before, the components of the CAC 40 are measured based on total market capitalization. However, since December 1, 2003, the CAC 40 had shift to a free-float index. Using this model, stocks are quarterly tracked based on free-float market capitalization and share turnover over the past 12-month period. A total of 40 companies are selected from the top 100 companies on Euronext Paris to compose the CAC 40.

The CAC 40 had posted its all-time high of 6,922.33 on September 4, 2000. During that day, it had a high of 6,944.77. Meanwhile, the all-time low of 893.82 had been recorded in January 1988.

The CAC 40 is an important indicator of investor sentiment not just in France but in all Europe. Along with other Euronext indices, it is closely watched by analysts and investors alike to predict the European economy.

Europe is already a successful region and yet it is still full of growth potentials. One of them is bioMérieux S.A.. Many investors are investing in CAC 40 stocks and it is clear why—the CAC 40 makes up a crucial part of the European economy.

More recent bioMérieux S.A. (EPA:BIM) news were published by: which released: “Endocrine Testing Market to Reach Worth US$ 7359.4 Million by 2025: Credence …” on March 14, 2018. Also published the news titled: “FDA Approves First Blood Test to Help Diagnose Brain Injuries” on February 15, 2018.‘s news article titled: “Cancer Biomarkers Market to Reach US $27.63 Billion by the End of 2025” with publication date: March 13, 2018 was also an interesting one.

bioM??rieux S.A. provides in vitro diagnostics solutions that determine the source of disease and contamination to enhance patient health and consumer safety worldwide. The company has market cap of 7.85 billion EUR. The firm offers reagents, instruments, software, and services for diagnosing infectious diseases, healthcare-associated infections, antimicrobial resistance, sepsis, acquired immunodeficiency syndrome, hepatitis, acute care and cardiovascular emergencies, and cancer; and for detecting microorganisms in agri-food, pharmaceutical, biotechnology, and cosmetic products. It has a 32.82 P/E ratio. The Company’s technologies and systems include clinical microbiology products, such as automated VITEK 2 system and Etest for the identification of bacteria and analysis of their susceptibility to antibiotics; VITEK MS, a mass spectrometry system for the identification of bacteria, fungi, and mycobacteria; culture media products; BacT/ALERT for the culture and detection of bacteria present in blood; lab solutions; and molecular diagnostics products.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.